NasdaqGS - Delayed Quote USD

Editas Medicine, Inc. (EDIT)

Compare
2.8800 -0.0300 (-1.03%)
At close: November 4 at 4:00 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Gilmore O'Neill M.D. President, CEO & Director 1.04M -- 1964
Dr. Linda C. Burkly Ph.D. Executive VP & Chief Scientific Officer 522.44k -- 1957
Dr. Baisong Mei M.D., Ph.D. Executive VP & Chief Medical Officer 654.9k -- 1964
Dr. Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member -- -- --
Prof. George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member -- -- 1954
Mr. Gregory Whitehead Executive VP and Chief Technical & Quality Officer -- -- --
Cristi Barnett Corporate Communications & Investor Relations -- -- --
Ms. Charlene Stern J.D., Ph.D. Executive VP & General Counsel -- -- --
Ms. Linea Aspesi Executive VP & Chief People Officer -- -- 1970
Ms. Caren Deardorf Executive VP and Chief Commercial & Strategy Officer -- -- 1965

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000 https://www.editasmedicine.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
265

Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2024 at 1:30 PM UTC - November 11, 2024 at 1:30 PM UTC

Editas Medicine, Inc. Earnings Date

Recent Events

November 4, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 17, 2024 at 5:20 PM UTC

at Cantor Global Healthcare Conference

September 5, 2024 at 8:30 PM UTC

at Wells Fargo Healthcare Conference

September 4, 2024 at 8:05 PM UTC

at Morgan Stanley Global Healthcare Conference

August 7, 2024 at 12:00 PM UTC

Q2 2024 Earnings Call

August 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 10, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

June 27, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers